Literature DB >> 2137384

Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance.

K R Copeland1, R W Yatscoff, R M McKenna.   

Abstract

Eight cyclosporine (CsA) metabolites were isolated from the urine of renal-transplant patients by high-pressure liquid chromatography. Structure and purity of the metabolites were assessed by fast atomic bombardment/mass spectroscopy, by proton nuclear magnetic resonance (NMR), and, when the quantity of metabolites permitted, by 13C-NMR. The immunosuppressive activities (I) of the metabolites were tested in three separate in vitro systems: primary and secondary mixed lymphocyte reactions as well as by a mitogen-stimulated system. The I, as measured by comparing the concentration of each metabolite required for 50% inhibition of incorporation of [3H] thymidine, varied among the assay systems, as did the ranking of I among the test systems. In general, the I of most metabolites in all assay systems were less than 10% of that for CsA. Metabolites with single modifications exhibited the greatest I; e.g., that of M-17 was congruent to 16% of that of CsA (potency ratio 0.16) in a secondary mixed lymphocyte reaction. The significance of these findings in relation to therapeutic monitoring of CsA is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137384

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

3.  [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].

Authors:  H Sperschneider; C Wagner; A Korn; U Christians
Journal:  Med Klin (Munich)       Date:  1997-10-15

4.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.